Agilent Technologies and SomaLogic Enter Agreement
News Aug 13, 2013
The companies will initially place SomaLogic's SOMAscan proteomic assay, which employs custom Agilent microarrays in its workflow, in select academic and contract research centers. Although the SOMAscan assay is already available to researchers directly from SomaLogic as a service, this planned roll-out is aimed at meeting the rapidly growing demand for access to SomaLogic's highly multiplexed, cost-effective proteomic analyses.
"This agreement will greatly enhance our current microarray offerings by expanding them into the rapidly growing proteomics market," said Jacob Thaysen, vice president and general manager of Agilent's Genomics Solutions Division. "SomaLogic's cutting-edge proteomic technology makes them an ideal partner for us to increase our presence in this growing market."
"Agilent's custom microarrays have been a critical element in our development of the SOMAscan assay over the past several years," said Larry Gold, Ph.D., chairman and CEO of SomaLogic. "We are delighted that our partnership is expanding to make the technology even more accessible to researchers everywhere."
Terms of the agreement were not disclosed.
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019